New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
06:22 EDTHZNPHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Subscribe for More Information
July 16, 2014
11:28 EDTHZNPHorizon Pharma management to meet with Jefferies
Meetings to be held in San Diego/San Francisco July 23-24 hosted by Jefferies.
July 14, 2014
10:16 EDTHZNPHorizon Pharma management to meet with JMP Securities
Meeting to be held in the Mid-Atlantic area on July 17 hosted by JMP Securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use